Process chemistry study demonstrates an efficient manufacturing route for an MCHr1 antagonist, highlighting scalable building blocks and soluble reducing reagents.
Process development work to provide an efficient manufacturing route to a MCHr1 antagonist is presented herewith. Features of this development work include a scalable manufacturing route to the useful 6-oxa-2-azaspiro[3.3]heptane building block and the use of a (soluble) alternative to sodium triacetoxyborohydride.
No takes yet. Share an insight, caveat, or question.
Golden et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: